Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma
American Journal of Clinical Oncology, 10/06/09
Papadopoulos NE et al. – Cisplatin-paclitaxel-dacarbazine regimen is effective in patients with advanced melanoma.
Methods- Chemotherapy-naive patients with surgically unresectable stage III/IV melanoma who had measurable lesions, no brain metastasis, and an Eastern Oncology Cooperative Group performance status of 0 or 1 enrolled
- Cohorts of 4 patients treated at each dose level
- Starting doses of drugs were as follows: cisplatin 20 mg/m2 IV on days 1 to 4, paclitaxel 100 mg/m2 IV on days 1 and 8, and dacarbazine 800 mg/m2 IV on day 1 only
- Doses of cisplatin and paclitaxel escalated to next dose level, until maximum tolerable doses reached
- Dose level without dose-limiting grade 4 toxicity chosen for phase II part of study
- Primary end point of phase II study to determine antitumor activity in terms of response rate and survival of patients
- Optimum chemotherapy doses for phase II study as follows: cisplatin 20 mg/m2 on days 1 to 4, paclitaxel 120 mg/m2 on days 1 and 8, and dacarbazine 800 mg/m2 on day 1
- 46 patients enrolled
- 2 complete and 17 partial responses seen for overall response rate of 41%
- Median overall survival time and time to tumor progression were 11.0 and 4.3 months
- Median response duration 6.2 months
- Myelosuppression and neuropathy were dose-limiting toxicities
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling
Oncogene, 12/04/09
Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma
Medical Oncology, 12/04/09
Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men
Cancer Causes and Control, 12/03/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
Cancer Treatment Reviews, 12/04/09
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
Cancer Treatment Reviews, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor